IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC [Accessibility Statement] Skip Navigation- B7H3/PTK7 co-expressed in 30-40% of multiple solid tumor types, including lung, breast, ovarian and colorectal cancers- Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161- Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNews ...